Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.48 |
| ▸ | AXL | P30530 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967274 | 0.91 | MET (0.46) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14969321 | 0.89 | MET (0.47) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14969007 | 0.88 | MET (0.47) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14968894 | 0.86 | NOTUM (0.47) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14968872 | 0.86 | MET (0.43) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14968984 | 0.86 | MET (0.51) | METAXLNOTUM | |
| SCHEMBL14969073 | 0.85 | KDM4E (0.46) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14969174 | 0.85 | KDM4E (0.43) | METAXLNOTUMKDM4ELMNA | |
| SCHEMBL14968985 | 0.83 | MET (0.50) | METAXLKDM4ELMNANPC1 | |
| SCHEMBL22511476 | 0.83 | MET (0.51) | METAXLNOTUMKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914731-B2 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | IGNYTA, INC. (US) | 2018-03-13 | — | — | US | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. | 2016-11-03 | — | — | US | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| CN-108047201-A | Uracil derivative as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2018-05-18 | — | — | CN | disclosed |
| EP-3309160-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | Ignyta, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9914731-B2 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | IGNYTA, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3087070-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015100117-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | MET 10/4885AXL 1/4885CNR2 1737/4885 |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | MET 5/4885AXL 1/4885CNR2 3539/4885 |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, FLT3 | MET 5/4885AXL 1/4885CNR2 2885/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | MET 5/4885AXL 1/4885CNR2 3539/4885 |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | AXL, RET, FLT3 | MET 5/4885AXL 1/4885CNR2 2885/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | MET 5/4885AXL 1/4885CNR2 3539/4885 |
| US-20160318929-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | MET 10/4885AXL 1/4885CNR2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.